Sandoz Tirzepatide Generic: FDA Accepts Applications to Rival Mounjaro and Zepbound

Sandoz just cleared an important hurdle. The FDA accepted the company’s applications for a generic version of tirzepatide. This is the drug behind Eli Lilly’s Mounjaro and Zepbound.

This isn’t a licensing deal. Sandoz built these products in-house. The company drew on its experience with small molecules, delivery devices, and biosimilar drugs. So the goal is simple: become the first company to offer a generic alternative to Mounjaro and Zepbound’s autoinjectors.

According to the company, the applications cover every indication tied to the original drugs. That means both type 2 diabetes and weight management made the cut, not just one or the other.

So what does tirzepatide actually do? It activates two different receptors, GIP and GLP-1, at the same time. This dual action helps regulate blood sugar in people with diabetes. It also curbs appetite, which explains the significant weight loss many patients see. Lilly sells the same molecule under two names depending on the use: Mounjaro for diabetes, Zepbound for weight loss. Both still require a prescription, and the FDA continues to oversee how they’re marketed.

Here’s where things get interesting from a business angle. Lilly’s patent on tirzepatide doesn’t expire until 2036. That’s still a decade away. So why file now? Sandoz likely wants to be ready the moment the door opens, instead of scrambling later. Other generic manufacturers are watching this space closely too, given how much demand has exploded for GLP-1 drugs.

Sandoz has been fairly direct about its ambitions. The company says its version could become one of the first generic tirzepatide products available to American patients once timing allows, potentially lowering the cost of treatment for many.

As for when that might happen, nobody knows yet. The FDA hasn’t set a specific timeline for this review process. Typically, the agency takes up to ten months to evaluate a generic application once everything is submitted. Still, acceptance for review is just step one. It doesn’t guarantee approval, and Sandoz can’t sell anything until the FDA signs off.

Why does this matter to regular patients? Mostly because of access and price. GLP-1 drugs have faced shortages for a while now, including semaglutide products like Ozempic and Wegovy. Manufacturers simply haven’t kept up with demand. If a generic tirzepatide eventually reaches pharmacy shelves, it could ease that pressure and reduce out-of-pocket costs for people managing diabetes or obesity.

One word of caution here. Compounded and unapproved versions have also flooded the GLP-1 market. The FDA has flagged real safety concerns about these products, since they skip the agency’s review entirely. So anyone considering tirzepatide or semaglutide should stick to prescriptions from licensed doctors, and use the FDA’s BeSafeRx resource to confirm a pharmacy is properly licensed.

For now, all eyes remain on the FDA’s review. If Sandoz clears it, the company could become the first to bring a generic tirzepatide injectable to the U.S. market, a milestone that would reshape competition in one of the fastest-growing drug categories in modern medicine.